Cargando…

Differential regulation of NF-κB activation and function by topoisomerase II inhibitors

BACKGROUND: While many common chemotherapeutic drugs and other inducers of DNA-damage result in both NF-κB nuclear translocation and DNA-binding, we have previously observed that, depending on the precise stimulus, there is great diversity of the function of NF-κB. In particular, we found that treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Kirsteen J, O'Shea, John M, Perkins, Neil D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459870/
https://www.ncbi.nlm.nih.gov/pubmed/16630341
http://dx.doi.org/10.1186/1471-2407-6-101
_version_ 1782127504270557184
author Campbell, Kirsteen J
O'Shea, John M
Perkins, Neil D
author_facet Campbell, Kirsteen J
O'Shea, John M
Perkins, Neil D
author_sort Campbell, Kirsteen J
collection PubMed
description BACKGROUND: While many common chemotherapeutic drugs and other inducers of DNA-damage result in both NF-κB nuclear translocation and DNA-binding, we have previously observed that, depending on the precise stimulus, there is great diversity of the function of NF-κB. In particular, we found that treatment of U-2 OS osteosarcoma cells with the anthracycine daunorubicin or with ultraviolet (UV-C) light resulted in a form of NF-κB that repressed rather than induced NF-κB reporter plasmids and the expression of specific anti-apoptotic genes. Anthracyclines such as daunorubicin can induce DNA-damage though inhibiting topoisomerase II, intercalating with DNA and undergoing redox cycling to produce oxygen free radicals. In this study we have investigated other anthracyclines, doxorubicin and aclarubicin, as well as the anthracenedione mitoxantrone together with the topoisomerase II inhibitor ICRF-193, which all possess differing characteristics, to determine which of these features is specifically required to induce both NF-κB DNA-binding and transcriptional repression in U-2 OS cells. RESULTS: The use of mitoxantrone, which does not undergo redox cycling, and the reducing agent epigallocatechingallate (EGCG) demonstrated that oxygen free radical production is not required for induction of NF-κB DNA-binding and transcriptional repression by these agents and UV-C. In addition, the use of aclarubicin, which does not directly inhibit topoisomerase II and ICRF-193, which inhibits topoisomerase II but does not intercalate into DNA, demonstrated that topoisomerase II inhibition is not sufficient to induce the repressor form of NF-κB. CONCLUSION: Induction of NF-κB DNA-binding and transcriptional repression by topoisomerase II inhibitors was found to correlate with an ability to intercalate into DNA. Although data from our and other laboratories indicates that topoisomerase II inhibition and oxygen free radicals do regulate NF-κB, they are not required for the particular ability of NF-κB to repress rather than activate transcription. Together with our previous data, these results demonstrate that the nature of the NF-κB response is context dependent. In a clinical setting such effects could profoundly influence the response to chemotherapy and suggest that new methods of analyzing NF-κB function could have both diagnostic and prognostic value.
format Text
id pubmed-1459870
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14598702006-05-13 Differential regulation of NF-κB activation and function by topoisomerase II inhibitors Campbell, Kirsteen J O'Shea, John M Perkins, Neil D BMC Cancer Research Article BACKGROUND: While many common chemotherapeutic drugs and other inducers of DNA-damage result in both NF-κB nuclear translocation and DNA-binding, we have previously observed that, depending on the precise stimulus, there is great diversity of the function of NF-κB. In particular, we found that treatment of U-2 OS osteosarcoma cells with the anthracycine daunorubicin or with ultraviolet (UV-C) light resulted in a form of NF-κB that repressed rather than induced NF-κB reporter plasmids and the expression of specific anti-apoptotic genes. Anthracyclines such as daunorubicin can induce DNA-damage though inhibiting topoisomerase II, intercalating with DNA and undergoing redox cycling to produce oxygen free radicals. In this study we have investigated other anthracyclines, doxorubicin and aclarubicin, as well as the anthracenedione mitoxantrone together with the topoisomerase II inhibitor ICRF-193, which all possess differing characteristics, to determine which of these features is specifically required to induce both NF-κB DNA-binding and transcriptional repression in U-2 OS cells. RESULTS: The use of mitoxantrone, which does not undergo redox cycling, and the reducing agent epigallocatechingallate (EGCG) demonstrated that oxygen free radical production is not required for induction of NF-κB DNA-binding and transcriptional repression by these agents and UV-C. In addition, the use of aclarubicin, which does not directly inhibit topoisomerase II and ICRF-193, which inhibits topoisomerase II but does not intercalate into DNA, demonstrated that topoisomerase II inhibition is not sufficient to induce the repressor form of NF-κB. CONCLUSION: Induction of NF-κB DNA-binding and transcriptional repression by topoisomerase II inhibitors was found to correlate with an ability to intercalate into DNA. Although data from our and other laboratories indicates that topoisomerase II inhibition and oxygen free radicals do regulate NF-κB, they are not required for the particular ability of NF-κB to repress rather than activate transcription. Together with our previous data, these results demonstrate that the nature of the NF-κB response is context dependent. In a clinical setting such effects could profoundly influence the response to chemotherapy and suggest that new methods of analyzing NF-κB function could have both diagnostic and prognostic value. BioMed Central 2006-04-21 /pmc/articles/PMC1459870/ /pubmed/16630341 http://dx.doi.org/10.1186/1471-2407-6-101 Text en Copyright © 2006 Campbell et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Campbell, Kirsteen J
O'Shea, John M
Perkins, Neil D
Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
title Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
title_full Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
title_fullStr Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
title_full_unstemmed Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
title_short Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
title_sort differential regulation of nf-κb activation and function by topoisomerase ii inhibitors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459870/
https://www.ncbi.nlm.nih.gov/pubmed/16630341
http://dx.doi.org/10.1186/1471-2407-6-101
work_keys_str_mv AT campbellkirsteenj differentialregulationofnfkbactivationandfunctionbytopoisomeraseiiinhibitors
AT osheajohnm differentialregulationofnfkbactivationandfunctionbytopoisomeraseiiinhibitors
AT perkinsneild differentialregulationofnfkbactivationandfunctionbytopoisomeraseiiinhibitors